Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion

被引:9
作者
Balaskas, Konstantinos [1 ,2 ]
Amoaku, Winfried M. [3 ]
Cudrnak, Tomas [4 ]
Downey, Louise M. [5 ]
Groppe, Markus [6 ]
Mahmood, Sajjad [7 ]
Mehta, Hemal [8 ]
Mohamed, Quresh [9 ]
Mushtaq, Bushra [10 ]
Severn, Philip [11 ]
Vardarinos, Athanasios [12 ]
Yang, Yit C. [13 ]
机构
[1] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[2] UCL, Inst Ophthalmol, London, England
[3] Univ Nottingham, Acad Ophthalmol, Div Clin Neurosci, Nottingham, England
[4] Univ Hosp Plymouth NHS Trust, Royal Eye Infirm, Plymouth, Devon, England
[5] Hull Univ Teaching Hosp, Kingston Upon Hull, N Humberside, England
[6] Buckinghamshire Healthcare NHS Trust, Ophthalmol Stoke Mandeville, Aylesbury, Bucks, England
[7] Univ Manchester, Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[8] Royal Free London NHS Fdn Trust, London, England
[9] Gloucestershire Hosp NHS Fdn Trust, Cheltenham Gen Hosp, Gloucestershire Eye Unit, Gloucester, England
[10] Sandwell & West Birmingham NHS Trust, Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England
[11] South Tees Hosp NHS Fdn Trust, Middlesbrough, Cleveland, England
[12] West Suffolk NHS Fdn Trust, West Suffolk Hosp, Eye Treatment Ctr, Bury St Edmunds, Suffolk, England
[13] Royal Wolverhampton NHS Trust, Wolverhampton Eye Infirm, Wolverhampton, England
关键词
Anatomical efficacy; Disease control fluid; OCT; Stability; OPTICAL COHERENCE TOMOGRAPHY; TREAT-AND-EXTEND; MACULAR DEGENERATION; VISUAL-ACUITY; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; THERAPY; RECOMMENDATIONS; MANAGEMENT;
D O I
10.1007/s40123-021-00342-5
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Neovascular age-related macular degeneration (nAMD) presents a significant treatment burden for patients, carers and medical retina services. However, significant debate remains regarding how best to manage nAMD when assessing disease activity by optical coherence tomography (OCT), and particularly the significance of different types of fluid and how the understanding of anatomical efficacy can influence treatment strategies. This article provides opinion on the practical implications of anatomical efficacy and significance of fluid in the management of nAMD and proposes recommendations for healthcare professionals (HCPs) to improve understanding and promote best practice to achieve disease control. Methods An evidence-based review was performed and an expert panel debate from the Retina Outcomes Group (ROG), a forum of retinal specialists, provided insights and recommendations on the definition, role and practical implications of anatomical efficacy and the significance of fluid at the macula in the management of nAMD. Results The ROG has developed recommendations for achieving disease control through a zero-tolerance approach to the presence of fluid in nAMD as patients who avoid fluctuations in fluid at the macula have better visual outcomes. Recommendations cover five key areas: service protocol, training, regimen, multidisciplinary teams and engagement. This approach facilitates more standardised protocol-based treatment strategies. Conclusions Targeting a fluid-free macula and aiming for disease control are essential to improve outcomes. As new therapies and technologies become available, drying the macula and maintaining disease control will become even more achievable. The outlined recommendations aim to promote best practice among HCPs and medical retina services to improve patient outcomes.
引用
收藏
页码:231 / 243
页数:13
相关论文
共 48 条
[1]  
AAO. American Academy of Ophthalmology Retina/Vitreo Panel, 2015, PREF PRACT GPATT GUI
[2]   Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group [J].
Amoaku, Winfried ;
Balaskas, Konstantinos ;
Cudrnak, Tomas ;
Downey, Louise ;
Groppe, Markus ;
Mahmood, Sajjad ;
Mehta, Hemal ;
Mohamed, Quresh ;
Mushtaq, Bushra ;
Severn, Philip ;
Vardarinos, Athanasios ;
Yang, Yit ;
Younis, Saad .
CLINICAL OPHTHALMOLOGY, 2018, 12 :1731-1740
[3]  
[Anonymous], OPHTHALMOLOGY
[4]   Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol [J].
Berg, Karina ;
Pedersen, Terje R. ;
Sandvik, Leiv ;
Bragadottir, Ragnheidur .
OPHTHALMOLOGY, 2015, 122 (01) :146-152
[5]  
Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
[6]  
Brown, 2013, RETINA TODAY, V2013, P73
[7]   ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION [J].
Brown, David M. ;
Tuomi, Lisa ;
Shapiro, Howard .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (01) :23-34
[8]   Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration [J].
Busbee, Brandon G. ;
Ho, Allen C. ;
Brown, David M. ;
Heier, Jeffrey S. ;
Suner, Ivan J. ;
Li, Zhengrong ;
Rubio, Roman G. ;
Lai, Phillip .
OPHTHALMOLOGY, 2013, 120 (05) :1046-1056
[9]   Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review [J].
Castillo, M. M. ;
Mowatt, G. ;
Lois, N. ;
Elders, A. ;
Fraser, C. ;
Amoaku, W. ;
Burr, J. M. ;
Lotery, A. J. ;
Ramsay, C. R. ;
Azuara-Blanco, A. .
EYE, 2014, 28 (12) :1399-1406
[10]   Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration A Systematic Review [J].
Castillo, Mayret M. ;
Mowatt, Graham ;
Elders, Andrew ;
Lois, Noemi ;
Fraser, Cynthia ;
Hernandez, Rodolfo ;
Amoaku, Winfried ;
Burr, Jennifer M. ;
Lotery, Andrew ;
Ramsay, Craig R. ;
Azuara-Blanco, Augusto .
OPHTHALMOLOGY, 2015, 122 (02) :399-406